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ABSTRACT: Herein, we report the rational, computationally-
guided design of an iridium(I) catalyst system capable of enabling
directed hydrogen isotope exchange (HIE) with the challenging
sulfone directing group. Substrate binding energy was used as a
parameter to guide rational ligand design via an in silico catalyst
screen, resulting in a lead series of chelated iridium(I) NHC-
phosphine complexes. Subsequent preparative studies show that
the optimal catalyst system displays high levels of activity in HIE,
and we demonstrate the labeling of a broad scope of substituted
aryl sulfones. We also show that the activity of the catalyst is
maintained at low pressures of deuterium gas and apply these conditions to tritium radiolabeling, including the expedient synthesis
of a tritium-labeled drug molecule.
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The incorporation of heavy isotopes into potential drugmolecules has, over time, become an indispensable tool
within the pharmaceutical industry.1 One of the most utilized
methods in this area is directed hydrogen isotope exchange
(HIE, Scheme 1), wherein hydrogen atoms ortho to a Lewis
basic directing group (DG) are replaced with deuterium or
tritium.2
Homogeneous iridium catalysts have been proven to be
highly active in ortho-directed HIE.3 These species have
enabled the use of a broad range of directing groups in the
labeling of small molecules and potential drug candidates.4
Related to this, studies within our own laboratory have led to
the development of a series of catalytically active iridium(I)
NHC/phosphine complexes 1−2 (Figure 1), which deliver
heavy isotopes of hydrogen (deuterium, D and tritium, T) to
aryl and alkenyl substrates via a directed C−H activation
process with a broad range of directing groups.3d,5 Addition-
ally, iridium(I) NHC chloride complexes of type 3 have shown
utility in the labeling of primary aryl sulfonamides and aryl
aldehydes.6
Despite these advances, however, certain high-value
functionalities, common throughout pharmaceutical motifs
and natural products, still present significant challenges for
directed HIE. One such example is the aryl sulfone unit, which
is prevalent throughout drug discovery.7 For example, sulfones
are present in antibiotics, such as dapsone and dextro-
sulphenidol,8a,b and are also components within a range of
other medicines, including the non-steroidal anti-inflammatory,
rofecoxib, and the retinoid, sumarotene (Figure 2).8c,d
However, the capacity to exploit the sulfone as a directing
group in C−H activation processes,9 including HIE,10 is
currently vastly undermet. With specific regard to HIE, Pfaltz
and Muri have reported an N,P-chelated Ir(I) catalyst, which
mediates deuterium labeling of a series of substrates, including
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Scheme 1. General Reaction Scheme for Directed HIE
Figure 1. Ir(I) precatalysts for directed HIE.
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one example of a simple aryl (phenyl methyl) sulfone. This
catalyst system does, however, require activation with elevated
pressures (2.2 bar) of deuterium.10a Nonetheless, the
abundance of the sulfone moiety in pharmaceutically active
agents makes the ability to exploit these functional units as
handles for ortho-directed HIE a particularly attractive goal.
Additionally, applying a mechanistic approach to such a
challenge has the potential to deliver an enhanced, and
potentially predictive, understanding of such directed
functionalization endeavors, enabling the use of sulfones in a
broader range of C−H activation processes.
Current iridium-catalyzed HIE processes directed by
sulfones have a range of limitations. For example, previous
studies within our laboratory toward sulfone-directed HIE have
employed monodentate iridium(I) catalysts, specifically NHC/
phosphine 1a and NHC/Cl analogue 3a. When these catalyst
systems were applied to the labeling of phenyl methyl sulfone
4a, low levels of incorporation were observed (Figure 3a).6a
We hypothesized that, in this case, substrate binding was
unusually the turnover-limiting step, in contrast to less
hindered directing groups where C−H activation is turnover
limiting.5c
Bearing in mind that catalysts 1−3 possess very large NHC
and (for 1 and 2) phosphine ligands, coordinated in a trans
relationship (Figure 3b), the tetrahedral nature of the sulfone
directing group results in significant steric repulsion between
the substrate and ligand when compared to more planar
directing groups, such as acetyl. This may inhibit substrate
binding, which in turn would severely limit the isotope
incorporation in sulfone-derived substrates, as observed with
1a and 3a.6a We hypothesized that the use of a tethered N-
heterocyclic carbene-phosphine ligand (NHC-P, Figure 3b)
would result in a less hindered catalyst environment, more able
to accommodate the sulfone unit.
The paradigm of rational ligand design is emerging as an
appreciably powerful tool through which the knowledge and
understanding gained from mechanistic insights allows an
effective catalyst to be accessed rapidly.11,12 We selected this
approach to address the challenge of developing a broadly
effective chelated catalyst system with the ability to label
sulfone-bearing substrates to high levels of isotope incorpo-
ration under mild reaction conditions. Specifically, a system
derived from rational, computational design would not only
provide a solution to the challenge of sulfone labeling but
would also potentially facilitate the application of the designed
system to a more diverse array of substrate classes.
To initiate our studies, and guided by our postulate that
substrate binding was limiting in the sulfone case (Figure 3),
computational modeling was used to calculate the binding
energy (EBind) of a model substrate methyl phenyl sulfone 4a
to catalytically relevant5c iridium(III) hydride complexes of
varying designs (Figure 4). The binding energy was calculated
using the counterpoise method, as described by Boys and
Bernardi.13 We observed that while methyl phenyl sulfone 4a
could coordinate to the monodentate NHC/phosphine
iridium(III) hydride derived from 1a (Figure 4a), a modest
binding energy of only −15.3 kcal mol−1 was calculated, with a
similarly poor binding energy of −15.9 kcal mol−1 for
precatalyst 3a (Figure 4b). To place these binding energies
in context, when the same method was applied to the binding
of acetophenone 5 (which has been shown to label to high
levels using precatalyst 1a5c), a significantly more negative and
Figure 2. Examples of sulfone-containing drug molecules.
Figure 3. Sulfone labeling: Challenges with monodentate catalysts
and a potential chelated catalyst solution.
Figure 4. Calculation of binding energy with monodentate ligand
systems.
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therefore more favorable binding energy of −23.1 kcal mol−1
was found (Figure 4c).
In terms of selecting a chelating ligand system to overcome
these binding issues, a number of tethered NHC-P ligand
motifs have been reported.14 Due to the range of tethers and
combinations of NHC and phosphine substituents already
established, an in silico screening was carried out to determine
which characteristics of the chelating ligand would lead to an
increased sulfone binding energy, and thus a potentially
effective catalyst system. Accordingly, we proposed a virtual
library of eighteen structurally diverse NHC-P ligands,
covering a number of chelate sizes (from four to seven
membered rings), and a range of steric and electronic
parameters, as dictated by the substituents on the NHC and
phosphine moieties. In each case, the binding energy of methyl
phenyl sulfone to the relevant chelated iridium(III) hydride
was calculated (Scheme 2).
Firstly, it was noted that only those ligands with N-aryl
substituents gave significantly higher sulfone binding energies
than the monodentate systems (cf. 6 vs 7). In general, ethylene
tethered systems (6, 9−13) showed a favorable range of
binding energies, from −23.7 kcal mol−1 for 13 to −29.5 kcal
mol−1 for 10. Also, aryl and alkyl phosphines both gave
enhanced binding energies when compared to the aforemen-
tioned monodentate catalysts. Furthermore, substitution on
the backbone of the NHC appeared to deliver a moderately
more favorable binding energy in some cases (cf. 12 vs 11).
The larger, benzyl-tethered ligands, 14−18, also showed
favorable sulfone binding energies with a similar pattern to
the corresponding ethylene-bridged systems being observed in
terms of the NHC substituent. Dicyclohexyl phosphinyl variant
16, however, displayed a reduced binding energy with respect
to the diphenylphosphinyl analogue 15 and, as such, no further
dialkylphosphines were considered. The effect of the chelate
ring size and rigidity was next examined, with the ortho-
phenylene, 19, methylene bridged, 20, and directly N-P bound
ligand, 21, all displaying favorable binding energies. Interest-
ingly, phosphite, 22, returned the highest binding energy of all
ligand variations examined. Finally, the benzimidazole-derived
NHC, 23, was also found to be favorable, resulting in a binding
energy of −30.8 kcal mol−1. The calculated binding energies
for each of the 18 bidentate complexes, as well as monodentate
complexes 1a and 3a, are shown graphically in Figure 5.
From this in silico screen, a total of six ligands (11, 13, 15,
17, 18, and 23) were selected for progression based on their
binding energy of methyl phenyl sulfone 4a, coupled with their
synthetic tractability in each case. The structures of the
targeted iridium(I) precatalysts 24−29 are shown in Figure 6,
with the selected ligands predicted to give complexes with a
range of substrate binding energies from −23.7 to −30.8 kcal
mol−1. The ligands for the iridium(I) precatalysts shown were
then synthesized via modification of existing literature
procedures.14d−g,15
With the iridium(I) precatalysts 24−29 in hand, their
labeling of methyl phenyl sulfone 4a was investigated. This
initial catalyst screen was performed at 25 °C in dichloro-
methane with a standard catalyst loading of 5 mol % and a
reaction time of 16 h. In the majority of cases (i.e., with the
exception of 25 and 27), a marked increase in the isotope
incorporation was observed compared to the monodentate
systems 1a and 3a (Table 1).
Based on the labeling results shown in Table 1, the most
promising catalyst, 29, was selected for further optimization,
beginning with a solvent screen and exploiting the versatility of
the catalyst’s BArF counterion in this regard.
5d As shown in
Figure 7, the observed incorporation reached significantly
higher levels in a broad range of solvents compared to the
initial labeling result in DCM. In particular, chlorobenzene and
fluorobenzene delivered the highest levels of labeling, affording
excellent 93 and 91% incorporations, respectively. Additionally,
the use of non-halogenated solvents such as di-iso-propyl ether,
MTBE, diethyl ether, and toluene also provided high levels
(>70%) of deuterium incorporation.
Accordingly, chlorobenzene was chosen as the optimal
solvent for this sulfone labeling process with catalyst 29. Not
only did this medium allow for the best incorporation from the
eleven solvents examined but also additional technical
advantages were delivered, in that the higher boiling nature
of chlorobenzene meant that cooling to −78 °C could be
avoided when exchanging the atmosphere within the reaction
manifold from nitrogen to deuterium, thus simplifying the
practical procedure. Notably, maintaining catalyst loadings at 5
mol %, the reaction time could be reduced to 1 h, with no drop
in the observed isotope incorporation.15 These conditions
were then applied to a broad range of aryl sulfones to establish
the scope of our developed process (Scheme 3). A total of
eighteen additional substrates were examined, encompassing a
diverse range of sulfones with generally excellent deuterium
incorporation effectiveness observed throughout the series.
Both electron-donating and electron-withdrawing substituents
Scheme 2. In Silico Screen of Bidentate Ligands and the
Calculated Binding Energy for Methyl Phenyl Sulfone
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in the ortho (4b−4d) and meta (4e−4 h) positions of the aryl
ring were well tolerated, leading to high levels of incorporation.
Notably, meta-trifluoromethyl substrate 4 g exhibits almost no
incorporation at the considerably hindered position between
both aryl substituents, but displays excellent levels of
deuterium labeling at the less hindered position ortho to the
sulfone. With less sterically encumbered meta substituents (4f
and 4 h) both positions ortho to the sulfone are labeled to a
high degree. A range of electronically distinct para-substituents
are also well tolerated (4i−4l, 4n). In the case of para-nitro
substrate 4 m, this alternative directing group is shown to
mildly outcompete the sulfone, but does not prevent an
acceptable level of isotope incorporation through sulfone-
directed HIE. Furthermore, restricting the orientation of the
sulfone, as in cyclic substrate 4o, did not result in a decrease in
the excellent levels of incorporation generally observed. We
next turned our attention to the effects of increasing the steric
bulk around the sulfone group, with substrates 4p−4r. While a
slight decrease in the levels of incorporated deuterium were
observed in diphenyl sulfone 4p and iso-propyl phenyl sulfone
4q (57 and 66%, respectively), an excellent incorporation of
80% was observed with the bulky tert-butyl phenyl sulfone 4r.
We also investigated labeling of benzyl methyl sulfone 4s,
where the sulfone would direct labeling via a 6-membered
metallacyclic intermediate (6-mmi), which is considerably less
favored than the more common 5-mmi.5c Nonetheless,
moderate levels of incorporation were still observed in this
more challenging substrate under these mild standard
conditions with a low catalyst loading of 5 mol %.
To further expand the utility of our newly developed catalyst
system, we investigated the effects of employing a reduced
pressure of deuterium gas using a TRITEC manifold system,
with these conditions more closely emulating those deployed
for radiolabeling with tritium gas within a pharmaceutical
industry setting. Following only minimal optimization of our
standard conditions,15 we obtained high levels of labeling
under these low-pressure conditions (Scheme 4). Employing
phenyl methyl sulfone 4a, it was found that with a deuterium
pressure of only ∼400 mbar, a mildly elevated catalyst loading
of 7.5 mol % allowed for similar levels of deuterium
Figure 5. Calculated binding energies with sulfone 4a.
Figure 6. Summary of the targeted Iridium(I) precatalysts.
Table 1. Catalyst Screena
entry catalyst % D incorporationa
1 1a 96a
2 3a 176a
3 24 35
4 25 12
5 26 23
6 27 13
7 28 36
8 29 43
aReactions performed in triplicate.
Figure 7. Solvent applicability in sulfone labeling.15
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incorporation to the standard (non-TRITEC) laboratory set-
up. Notably, when employing the most active catalyst reported
by Pfaltz and Muri,10a very low levels of labeling of this same
substrate, 4a, were observed when employing 1 atm of D2 for
catalyst activation,15 as is routinely employed with our suite of
Ir(I) catalysts, including 29. Indeed, the requirement for supra-
atmospheric catalyst activation with this previously reported
system may present practical challenges when applying the
methodology to low-pressure tritiations (vide infra).
With a successful reduced atmosphere protocol in hand
using catalyst 29, the conditions were then applied to the
tritium labeling of the same sulfone 4a. Exposure of 4a to 7.5
mol % of precatalyst 29 under 405 mbar of tritium gas afforded
t-4a with a high activity of 51.3 Ci/mmol, corresponding to a
tritium incorporation of 88% across both ortho positions.
Additionally, the major mass ion of [M + 4] confirmed that the
sample had indeed been labeled with two units of tritium
(Scheme 4).
Finally, to further demonstrate the power of our developed
catalyst as applied to radiolabeling, as shown in Scheme 5 we
targeted a tritium-labeled sample of the highly potent GPR119
agonist 30.16 Accordingly, benzylic bromide-containing sulfone
4t could be readily tritiated and alkylated in one pot to afford t-
30 with excellent levels of radiolabel incorporation.
In conclusion, we have employed a computationally-guided,
rational ligand design approach to target a series of iridium(I)
NHC-P complexes for the directed HIE of aryl sulfones. The
resulting optimal complex proved to be highly active in a range
of solvents, and an extensive substrate scope has been
established, with high levels of deuterium incorporation
being exhibited across the series. Furthermore, the catalyst
system has been shown to retain its activity when applied to
the low-pressure labeling systems currently used extensively in
the pharmaceutical industry. Finally, the emerging iridium(I)
NHC-P catalyst has been applied to tritium labeling, furnishing
a selectively tritiated sample of GPR119 agonist t-30 with high
levels of specific activity. Our current studies are focused on
extending our understanding of these catalytic systems in order
to further refine our design process to encompass even more
challenging substrates.
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